Sign up today to have the latest news in drug development worldwide delivered to your inbox ~ DIA's Global Smartbrief
Subscribe to the DIA Daily.View archives.
iPhone and iPad Apps available! Download "BulletinHC."DIA Daily is a digest of the most important news selected from thousands of sources by the editors of BulletinHealthcare. The presence of content or advertising does not endorse, nor imply endorsement of, any products or services by the Drug Information Association. Neither BulletinHealthcare nor the Drug Information Association is liable for the use of or reliance on any information contained in this briefing.
If you would like more information about, or have a question pertaining to, DIA Membership and its benefits, please email membership@diahome.org.Click here to check your membership status.
Drug Information Association | 800 Enterprise Road, Suite 200 | Horsham, PA 19044 Copyright © 2012 by BulletinHealthcare| 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191
US
District Judge Edward Korman's decision Friday to reverse age restrictions on
over-the-counter access to emergency contraceptive products was covered by all
three broadcast networks, two which led with the story. Most of the media
coverage noted Judge Edward Korman's frustrations with Health and Human
Services Secretary Kathleen Sebelius having overruled a 2011 Food and Drug
Administration recommendation to allow emergency contraception to be sold OTC
to all ages; and several outlets noted that Korman, who presides over the
District Court of Eastern New York, also placed some of the blame on the FDA
for restricting access to the morning-after products in the past.
The CBS Evening News (4/5, lead story, 3:10, Pelley) opened by reporting,
"Anyone of any age may soon be able to walk into a drugstore and buy the
morning-after pill. ... Throwing the dictionary at the Administration, Judge
Edward Korman called the rule 'arbitrary, capricious, unreasonable and
obviously political.'" CBS (Cordes) added that at the time of her 2011
decision, HHS Secretary Kathleen Sebelius "had argued younger girls might
not understand the drug's labeling, leading to misuse."
NBC Nightly News (4/5, lead story, 2:50, Williams) opened by saying, "This
is a medical issue. It's a social issue. It's a moral issue for a lot of
people." NBC (Gosk) added, "Barring an appeal, the legal battle over
the drug and who should be allowed to buy it is over." On ABC World News
(4/5, story 3, 2:15, Muir), Amy Robach reported, "Girls can soon be able
buy the morning-after pill, 'Plan B', as easily as a bottle of aspirin."
The AP (4/5) reported President Obama "had supported
the 2011 decision setting age limits, and White House spokesman Jay Carney said
Friday the president hasn't changed his position. 'He believes it was the right
common-sense approach to this issue,'" Carney said.
In a front-page story, the New York Times (4/6, A1, Belluck, Subscription
Publication) reported that Judge Korman's decision "counteracts an unprecedented
move" in 2011, by Secretary Sebelius, who "overruled" an FDA
recommendation. In 2011, FDA Commissioner, Dr. Margaret A. Hamburg released a
statement "saying that after rigorous study, it was safe to sell Plan B
One-Step [levonorgestrel] over the counter for all ages." Moreover, the
Times pointed out that scientists, "including those at the FDA, have been
recommending unrestricted access for years, as have major medical groups,
including the American Medical Association, the American Congress of
Obstetricians and Gynecologists and the American Academy of Pediatrics."
ABC News (4/6, Lupkin) on its website pointed
out that Plan B, which prevents a "fertilized egg from attaching itself to
the uterine wall," has been sold OTC in "China since 1998, and a
study published in 2011 in the journal Human Reproduction involving 2,521 women
found no adverse side effects. The most common side effects were vaginal
bleeding and headaches."
USA Today (4/5, Stanglin) reported that in his
"59-page ruling," Judge Korman "said that Sebelius, in
overruling the FDA, had forced the agency to 'to ride roughshod over the
policies and practices that it has consistently applied in considering applications
for switches in drug status to over-the-counter availability.'" Korman
also "noted that the FDA itself had engaged in its own foot-dragging over
the years, dating from the Bush administration, when the plaintiffs first began
trying to get it to rule on Plan B more than 12 years ago. 'The FDA has engaged
in intolerable delays in processing the petition,' he wrote."
According to the Washington Post (4/6, Kliff, Dennis), the FDA
initially, "approved Plan B as a prescription emergency contraceptive in
1999" and in 2003, its manufacturer asked the agency permit OTC sales of
the drug but the "FDA rejected that request, citing a lack of data on how
the drug affected young teenagers." However, two "FDA officials
resigned" in 2005, after the "agency announced plans to indefinitely
postpone any further review" of permitting OTC sales of Plan B.
"Susan Wood, former director of the FDA's Office of Women's Health and one
of the officials who resigned in 2005, thinks the changing political landscape
could finally put an end to the decade-long controversy."
Bloomberg News (4/6, Pearson, Armour) added
that Korman "excoriated" the FDA for the delay in making Teva
Pharmaceutical Industries' "Plan B, available over the counter. ... 'These
emergency contraceptives would be among the safest drugs sold over the
counter,' Korman wrote, and 'the number of 11-year-olds using these drugs is
likely to be minuscule.'" FDA spokesperson Erica Jefferson "declined
to comment on the ruling or the possibility of an appeal to the US Court of
Appeals in New York."
The Christian Science Monitor (4/6, Richey) said
Korman, a "Reagan nominee, has presided over the Plan B litigation for
years. In 2009, he ordered the Food and Drug Administration to expand
availability of the drug without prescription to 17-year-olds."
The Wall Street Journal (4/6, A3, Kendall,
Anderson, Subscription Publication) reported that on Friday, Korman gave the
FDA 30 days to lift the age restrictions from the Plan B emergency
contraceptive and its generic equivalents. NBC News (4/6, Aleccia) in its
"Vitals" blog added that Korman gave the FDA "the option of
limiting the expanded access to the Plan B One-Step single-pill product if the
agency 'actually believes there is any significant difference between the one-
and two-pill products.'"
The Philadelphia Inquirer (4/7, McCullough) noted
that at present, the Plan B One-Step and Next Choice are "available
without a prescription only to women 17 and older. The products are also kept
behind the pharmacist's counter; purchasers must show a government-issued ID
with proof of age."
According to the Los Angeles Times (4/6, Morin) "Booster
Shots" blog, the "ruling comes in response to a lawsuit filed by the
Center for Reproductive Rights, which argued that restrictions placed on the
drug imposed unreasonable delays for women of all ages" because the age
prohibitions forced pharmacists to keep the products "behind counters so
that they were not available outside regular business hours." US
Department of Justice spokesperson Allison Price "said the government was
'reviewing the appellate options and expects to act promptly.'"
Meanwhile, The Hill (4/5, Viebeck)
"Healthwatch" blog noted that the Korman's decision "won praise
from the medical community and supporters of abortion rights, who have
litigated cases involving emergency contraception since 2001. 'Today science
has finally prevailed over politics,' said" Center for Reproductive Rights
CEO Nancy Northup.
Similarly, CQ (4/6, Norman, Subscription Publication)
said supporters "characterized the ruling as a major victory that will
open the door to wider use of a safe and effective drug." Conversely, that
puts "Obama and Sebelius on the side of some of the same groups that they
are fighting in court over a separate requirement that all FDA-approved
contraceptives - including the morning-after pill - be covered in workers'
health insurance plans as preventive services under the health care law,"
CQ noted.
In contrast, the Boston Globe (4/6, Kotz) reported that critics
said the ruling means "young teens might indiscriminately incorrectly use
the morning after pill as a method of birth control and that it might encourage
sexual promiscuity. 'The decision will give young girls a serious drug,' said
Anne Fox, president of the Massachusetts Citizens for Life, an antiabortion
group. 'I think it's very irresponsible,'" Fox added. In the meantime, the
Federal government is "expected to release its final rules for coverage of
birth control methods such as oral contraception and intrauterine devices
within the next few weeks."
The ruling was also covered by the Atlantic (4/6, Hamblin), the New York Daily News (4/6, Marzulli, McShane),
the New York Post (4/6, Maddux), Politico (4/6, Smith), the CNN (4/5, Landau) website, MSNBC (4/6, Cowley) on its website, the Time (4/6, Sifferlin) "Healthland"
blog, the Dayton (OH) Daily News (4/6, McCarty), the Daily Caller (4/6, May), the NPR (4/6, Rovner) "Shots" blog, Reuters (4/6, Dye), BBC News (4/6), MedPage Today (4/6, Neale) and HealthDay (4/6, Reinberg).
NYTimes: Ruling Admonishes Administration's Politically Motivated
Decision. The editorial board of the New York Times (4/6, A16, Subscription
Publication) opined that Korman's decision to overturn the Obama
Administration's "ban preventing girls younger than 17 from purchasing
emergency contraceptive" products OTC, was a "well-deserved rebuke to
a politically motivated decision that overrode sound science and the health
needs of young girls in order to placate political opponents of emergency
contraception."
NYSun: "Plan C" Should Deal With Parental Authority. The New York Sun (4/8) editorializes that Korman's
ruling "has ignited quite an uproar" among parents on both "the
right and left, including, it turns out, the President." Korman did not
make it "his job to rule on the moral issues" or on "what one
might call the good parenting issues," both of which are "better
dealt with in the Congress or what we are sometimes prone to call 'Plan
C.'" The Sun concludes that at this point, the "right move for
Congress would be to reinforce the authority of the parents, who, after all,
would be paying for any pills any 11 year old purchases."
Bloomberg
News: Sebelius Should Let Ruling Stand. Bloomberg News (4/5) editorialized that many
physicians have "explained," that they oppose age restrictions
because the morning-after products are "most effective if taken within 24
hours of unprotected sex" and quite often, there "isn't time for
users to see a doctor before going to the pharmacy." In fact, Bloomberg
News pointed out, "last November, the American Academy of Pediatrics
recommended that its members work around the age restriction by prescribing the
drug to teens in advance." The editorial also noted that several other
physician groups, including the AMA, have voiced support for lifting the access
restrictions on emergency contraceptives. Now, with the "presidential
election that loomed" over Secretary Sebelius' "2011 action well
past, she should let the judge's order stand," Bloomberg News concluded. DIA Daily. This daily enewsletter features summaries of breaking news and information about the pharmaceutical, biotechnology, and medical device fields from thousands of global news sources. This easy-to-read enewsletter is delivered to your inbox every business morning. |
Subscribe to the DIA Daily.View archives.
iPhone and iPad Apps available! Download "BulletinHC."DIA Daily is a digest of the most important news selected from thousands of sources by the editors of BulletinHealthcare. The presence of content or advertising does not endorse, nor imply endorsement of, any products or services by the Drug Information Association. Neither BulletinHealthcare nor the Drug Information Association is liable for the use of or reliance on any information contained in this briefing.
If you would like more information about, or have a question pertaining to, DIA Membership and its benefits, please email membership@diahome.org.Click here to check your membership status.
Drug Information Association | 800 Enterprise Road, Suite 200 | Horsham, PA 19044 Copyright © 2012 by BulletinHealthcare| 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191
No comments:
Post a Comment